{"pageContent": "Introduction: Phosphodiesterase type 5 inhibitor (PDE5) use is a treatment strategy for prostate cancer patients with post-radiation therapy (RT) erectile dysfunction (ED).", "metaData": {"source": "Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention\nhttps://pubmed.ncbi.nlm.nih.gov/15986401/"}}